Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Soleno Therapeutics (SLNO) Cash from Financing Activities: 2014-2018

Historic Cash from Financing Activities for Soleno Therapeutics (SLNO) over the last 3 years, with Dec 2018 value amounting to $16.3 million.

  • Soleno Therapeutics' Cash from Financing Activities rose 15.05% to $16.3 million in Q4 2018 from the same period last year, while for Dec 2018 it was $17.8 million, marking a year-over-year decrease of 40.31%. This contributed to the annual value of $213.0 million for FY2024, which is 18.33% up from last year.
  • Latest data reveals that Soleno Therapeutics reported Cash from Financing Activities of $16.3 million as of Q4 2018, which was up 2,228.86% from $700,000 recorded in Q3 2018.
  • Soleno Therapeutics' 5-year Cash from Financing Activities high stood at $16.3 million for Q4 2018, and its period low was $133 during Q4 2016.
  • Moreover, its 3-year median value for Cash from Financing Activities was $2.9 million (2016), whereas its average is $5.3 million.
  • As far as peak fluctuations go, Soleno Therapeutics' Cash from Financing Activities slumped by 100.00% in 2016, and later spiked by 10,654,035.34% in 2017.
  • Quarterly analysis of 5 years shows Soleno Therapeutics' Cash from Financing Activities stood at $9.5 million in 2014, then crashed by 55.86% to $4.2 million in 2015, then crashed by 100.00% to $133 in 2016, then surged by 10,654,035.34% to $14.2 million in 2017, then increased by 15.05% to $16.3 million in 2018.
  • Its Cash from Financing Activities stands at $16.3 million for Q4 2018, versus $700,000 for Q3 2018 and $537,000 for Q2 2018.